About: Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 2003

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 2003 (uk) article scientifique publié en 2003 (fr) im Juli 2003 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 2003 (ast) scientific article published on 01 July 2003 (en)
publication date	wds:Q73628374-18EDFFDE-A228-4A4F-9F11-3BC4BB5AC4C9
publication date	2003-07-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q73628374-1C7E09F4-4942-46B6-8802-98BA743084BE wds:Q73628374-231740F1-F021-4FC0-99FF-6B01673701F7 wds:Q73628374-5F686791-64D2-414D-9730-726A4688FE6E wds:Q73628374-78A0CF23-DD0E-4F6D-AF2A-7D6793180A53 wds:Q73628374-83196029-5352-4C50-A032-61EBF948F203 wds:Q73628374-8DC69E5E-0607-42E0-B2B0-13340D61E903 wds:Q73628374-9D6944AD-2DF6-4EB7-88BA-22B577576375 wds:Q73628374-B7175FCA-40A4-49CD-A0E1-74E0BD8C9B14 wds:Q73628374-D8FE7CA2-F089-4A5C-8F6E-41348F659DDB
author name string	Yannick Allanore Bruno Fautrel Maxime Dougados Francis Berenbaum Jacques-Eric Gottenberg Jean Sibilia Fabrice Bentaberry Antoine Durbach Florence Merle-Vincent
rdfs:label	Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (en) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (nl)
skos:prefLabel	Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (en) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (nl)
name	Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (en) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (nl)
author	wds:Q73628374-044F8D13-34AE-46A2-B394-0545A3596B46 wds:Q73628374-103B9148-B797-45BB-9F94-8F94D26328FB
author	Bernard Combe Xavier Mariette
title	wds:Q73628374-CF4C916A-CA65-458D-8182-0029EDD63983
title	Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy (en)
page(s)	wds:Q73628374-6CC5D333-DF95-462B-B300-54E0D7B2D733
page(s)	2019-2024
instance of	wds:Q73628374-91CB5810-1E91-40E3-A2F2-F1FECEF449F4
instance of	scholarly article
main subject	wds:Q73628374-7E61E3A9-AC66-4556-9BEF-5F5D21325691
main subject	AA amyloidosis
PubMed ID	wds:Q73628374-C090A235-C953-4409-8780-D298C9F53C65
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12847696
PubMed ID	12847696
published in	wds:Q73628374-C69BFBE0-2FA3-46C2-BB0A-4D1DAB9E0620
published in	Arthritis and Rheumatism
issue	wds:Q73628374-BFBEE082-E327-426F-951F-B6F56EE71077
volume	wds:Q73628374-65BA3514-34AC-4124-B987-B74FF312F9E8
issue	7
volume	48
DOI	wds:Q73628374-FF0AA7D9-C814-4F8A-8B05-A6D205351236
DOI	http://dx.doi.org/10.1002/ART.11163
DOI	10.1002/ART.11163
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73628374
is cites work of	Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Successful treatment of chronic tophaceous gout with infliximab (Remicade) Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab Systemic amyloidosis: a challenge for the rheumatologist Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Secondary amyloidosis in ankylosing spondylitis. Renal amyloidosis in children Methotrexate for rheumatoid arthritis patients who are on hemodialysis Anti-tumour necrosis factor alpha therapy in patients with impaired renal function Podocyte directed therapy of nephrotic syndrome-can we bring the inside out? A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. wd:Q95359600 Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept wd:Q95359062 AA amyloidosis in psoriatic arthritis wd:Q95359191 Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis. AA amyloidosis in the renal allograft: a report of two cases and review of the literature. Duodenal amyloidosis secondary to ulcerative colitis. Single Nodular Pulmonary Amyloidosis: Case Report Renal manifestations in rheumatic diseases [Inflammatory bowel disease and amyloidosis] [Extra-articular manifestations and complications of ankylosing spondylitis] Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents Author's reply wd:Q95359201 Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software